ABSTRACT Background: National survey data of erythrocyte glutathione reductase activation coefficient (EGRac) indicate that suboptimal riboflavin status may be a problem in all population age groups, but the cutoff for deficiency is controversial. In addition, the effectiveness of different biomarkers of riboflavin status has not been critically evaluated. Objective: We aimed to assess the effectiveness of different biomarkers of riboflavin status through a systematic review of published riboflavin supplementation trials. Design: We structured our search strategy on Ovid MEDLINE, EMBASE (Ovid), and Cochrane databases; formal inclusion and exclusion criteria; data extraction; validity assessment; and metaanalysis.
INTRODUCTION
The main dietary sources of riboflavin (vitamin B-2) are milk and other dairy products and fortified foods such as breakfast cereals (1, 2) . Dietary recommendations for riboflavin range from 1 to 1.8 mg/d (3) (4) (5) , and mean intakes in European countries are generally reported to be higher than these recommendations (6, 7) . Riboflavin occurs predominantly in food in the form of flavin adenine dinucleotide (FAD), with smaller amounts of flavin mononucleotide (FMN) and free riboflavin present. FAD and FMN are hydrolyzed to free riboflavin by nonspecific phosphatases before absorption, which occurs mainly in the proximal small intestine by an active system that is carrier mediated and saturable at a dose of 27 mg from a single meal (8, 9) . Intracellular metabolism involves phosphorylation of riboflavin to form FMN with further conversion to FAD, which accounts for the majority of riboflavin in plasma and tissues (8) .
The coenzymes FAD and FMN have many biological functions. They act as cofactors for several enzymes involved in redox reactions and in the metabolism of other B vitamins (folate, vitamin B-6, and niacin). Such enzymes can be FAD dependent, such as methylenetetrahydrofolate reductase (MTHFR), which plays an important role in folate and homocysteine metabolism, and the erythrocyte enzyme glutathione reductase (GR), or FMN dependent, such as the enzyme pyridoxine phosphate oxidase (PPO), which converts dietary vitamin B-6 to the biologically active form, pyridoxal phosphate. The test most widely used to assess riboflavin status measures the activity of GR before and after in vitro reactivation with its prosthetic group FAD. The erythrocyte glutathione reductase activation coefficient (EGRac) is calculated as the ratio of FAD-stimulated to unstimulated enzyme activity and is considered to indicate the degree of tissue saturation with riboflavin. This test is less useful under certain conditions, such as glucose-6-phosphate dehydrogenase deficiency where the GR enzyme is saturated with FAD regardless of riboflavin status (10) , resulting in a limited response of enzyme activity to supplementation (11) .
Clinical riboflavin deficiency (typically presenting as angular stomatitis, cheilosis, and glossitis) is common in developingcountry populations (11, 12) but rare in Western societies. In the United States, mandatory fortification of flour with riboflavin has been in place since the 1940s, which has ensured generally higher intakes on a population-wide basis irrespective of individual dietary practices. However, elsewhere there is some evidence to suggest that suboptimal riboflavin status, as determined by the functional marker EGRac, might be a widespread problem affecting many population subgroups. National surveys from the United Kingdom show that the prevalence of EGRac .1.3 was 66% among adults aged 19-64 y (13) , and although prevalence decreased with increasing age, 41% of adults aged .65 y had suboptimal status (14) . Furthermore, EGRac values in apparently healthy older people can be lowered by supplementation with physiologic and pharmacologic doses of the vitamin (15) . Although current dietary recommendations for riboflavin in the United Kingdom (3) and in the United States (4) are based on intakes associated with EGRac values within the normal range, there is uncertainty about the EGRac cutoff that should be used to define deficiency.
The primary aim of this study was to conduct a systematic review of intervention studies with riboflavin in humans to identify the biomarkers of status that reliably reflect change in riboflavin intake.
SUBJECTS AND METHODS
Our methodology was based on the standard methodology developed for this set of reviews (16) in this supplement issue and is summarized below, where we emphasize any differences from the main methodology.
Inclusion criteria
To be included in this review, a study needed the following: 1) to be a supplementation and/or depletion study, 2) to be conducted in humans, 3) to include a placebo or untreated comparison group, 4) to be supplemented with riboflavin in the form of oral supplements or fortified foods or through natural food sources, 5) to report riboflavin status at baseline and for at least one time point after supplementation, and 6) to be published in English or in another European language. No minimum duration of supplementation was defined to ensure that valid studies were not missed (eg, those that measured urinary excretion of riboflavin that responds rapidly to a change in status).
Exclusion criteria
Studies were excluded if they met any of the following criteria: 1) were conducted in patient groups with preexisting disease on the basis that the biomarker responses might not have been representative of the general population or the disease state might have confounded the outcomes, 2) administered riboflavin in combination with other nutrients or another intervention if the independent effects of riboflavin could not be identified, 3) did not report variance data, and 4) were acute studies (ie, typically one dose with measurement of hourly responses).
Search strategy

Electronic searches
Ovid MEDLINE (1950-week 2, September 2007; www.ovid. com), EMBASE (Ovid, 1980 (Ovid, -week 37, 2007 ; www.ovid.com), and the Cochrane Library CENTRAL database (inception to 20 September 2007; www.thecochranelibrary.com) were searched for intervention studies of riboflavin using text terms with appropriate truncation and relevant indexing terms. The search was in the following form: riboflavin terms AND intervention terms AND human studies. The full Ovid MEDLINE search strategy can be found in Supplemental Table 1 under ''Supplemental data'' in the online issue, and the search strategies for the other databases were based on this approach.
Reference search
An additional Ovid MEDLINE search was conducted (1950-week 2, September 2007) for reviews of methods of assessing riboflavin status. Five of these reviews were collected in full text (8, (17) (18) (19) (20) , and the reference lists were checked for studies that appeared to be intervention studies not already assessed for inclusion. In addition, reference lists of the original articles included in this systematic review were also scrutinized for any potential articles not identified by the searches. Unpublished studies were not included in this review.
Data collection
Titles and abstracts were screened for inclusion by a single reviewer and duplicates were removed. Full-text articles were obtained for potentially suitable articles and for those where suitability was unclear from the screening stage. The full text of all articles collected was screened for inclusion using an inclusion and exclusion form by a single reviewer. Data for each included study were extracted onto a Microsoft Access (Microsoft Corp, Redmond, WA) database file by a single reviewer; 20% of extracted data was then checked by a second reviewer. No disagreements occurred between the 2 reviewers. The complete duplication of the screening of articles for inclusion and exclusion and data extraction as suggested in the main methodology article (16) could not be achieved because of time constraints. The data extraction form was tested on a small number of articles by a single reviewer and discussed with the review team before beginning full data extraction.
Data extraction was as discussed in the main methodology article (16) with the following additions. Corresponding authors of 5 articles were contacted to obtain missing data (21) , to clarify data (22, 23) , or to obtain mean (6SD) change from baseline values where this information was not evident in the original publication (21, 24, 25) . For one of these studies (25) , pre-and postsupplementation data were requested for the treatment groups before and after the removal of those homozygous for the common 677C/T polymorphism in the MTHFR gene (TT genotype, affecting '10% of white populations; 26) because participants with the TT genotype were preselected in the study design and were therefore overrepresented in the sample compared with the general population. Those with the TT genotype were examined separately and only included in the subgroup analysis specifically for the effect of genotype.
Data synthesis
Primary and secondary measures of interest were as stated in the main methodology article (16) , and data synthesis was carried out as described in that article with the following additional decisions and/or assumptions made for this article. Publications that reported data from the same study were linked and treated as one supplementation study. This procedure applied to the following studies. McKinley (27) was considered to be the main publication with Hustad (24) reporting additional data from this study. In a placebo-controlled trial in which pregnant and lactating women received ferrous sulfate and/or riboflavin, one article (11) combined the 2 groups who received riboflavin alone or in combination with ferrous sulfate with the 2 groups who received placebo or ferrous sulfate for statistical analysis. The latter publication (11) was used in this review for the main and most of the secondary analyses because the authors stated that the iron supplement had no effect on the outcomes of interest here, and the sample size was larger than that of related research (28) on the basis of a subgroup from the same sample that included only groups that received riboflavin or a placebo alone. The data from the related publication (28) were used for the subgroup analysis by age group as the data in this article were presented separately for pregnant and lactating women. One publication reported on 2 separate placebo-controlled trials (29) and one presented data for 2 subgroups separately (ie, early lactation and late lactation; 21); in both cases these groups were treated as 2 independent studies in the analysis. Subjects with the MTHFR 677 TT genotype who participated in a randomized controlled trial (RCT; 25) were excluded from the main analysis and all secondary analyses other than subgroup analysis by genotype to ensure that the data were more representative of the general population (given the study design that involved initial screening to preselect for this genotype). Data were extracted from figures for 2 studies (22, 30) , and for one of these studies the data presented were assumed to be mean 6 SD (22) . Where studies differed in the units used for reporting data, all data (mean 6 SD) were converted to SI units. If the measure of variance was reported as SEM (21, 23, (30) (31) (32) (33) , the SD was estimated from these values. This estimate was not possible for one study because the n values in each treatment group were unclear from the publication (23) . In studies that included 2 riboflavin treatment groups and one common control group (15, 29, 31, 34) , the lower dose or doses administered were included only in the secondary analysis (ie, the subgroup analysis by dose). However, for the secondary analysis, if both riboflavin treatment arms fell within the same range for dose, the groups were combined according to the Cochrane formulas for combining groups (35) . Several studies measured response at more than one time point, and again the shorter study durations were included only in the secondary analysis (ie, the subgroup analysis by duration; 21, 28, 30, 36) . For the presentation of data, responses to intervention were shown in the same plot whether they were presented as change from baseline values (25, 28, 32, 37) or as absolute values postintervention (11, 15, 21, 22, 27, 29, 30, 33, 36, 38) .
RESULTS
The flow diagram outlining the search results for this review is shown in Figure 1 . After the removal of duplicates, 1665 titles and abstracts were screened. Of these, the majority of articles (1629) were excluded primarily because they were review Analytic method: enzyme assay on the Cobas centrifugal analyzer described by Powers et al, 1983 (cited in the original publication).
Study aim: to determine whether riboflavin in addition to iron improves hematological status in pregnant and lactating women. Comments: study conducted during the rainy season. For the main and the majority of subgroup analysis, data from the placebo and the iron group combined and from the riboflavin and the riboflavin and iron group combined were used. Those who were genetically abnormal (ie, had sickle cell trait or were glucose-6-phosphate dehydrogenase deficient) were excluded.
(Continued) Analytic method: enzyme assay described by Powers et al, 1983 (cited in the original publication). Analytic method: enzyme assay on the Cobas Fara centrifugal analyzer described by Powers et al, 1983 (cited in the original publication). Study aim: to investigate the effect of riboflavin supplementation on homocysteine concentrations.
(Continued) No. in control at latest time point: 26
As above
As above Comments: two more groups treated with folic acid or folic acid and riboflavin were excluded from the data extraction. Capsules taken 3 times/d after meals. At baseline, the riboflavin-treated group had significantly higher homocysteine concentrations than the control group.
(Continued) (24) RCT. Double-blind study. A laboratory technician not involved in the study randomly assigned subjects to treatment groups.
Intervention, n ¼ 1; control, n ¼ 1. Withdrew because of illness.
Participants visited at home every 3 wk and unused tablets counted. Only one subject missed more than 2 tablets during the study (subject was included in the analysis). McNulty et al, 2006 (25) RCT. Double-blind study. For each of the 3 genotype groups, participants stratified according to homocysteine concentrations and randomly assigned to treatment group.
Five subjects withdrew voluntarily or were withdrawn because of failure to return pillboxes or to provide a final blood sample. Seven (non-TT genotype) subjects excluded because they had normal riboflavin status on rescreening and were therefore ineligible for inclusion.
Participants provided supplements every 2 wk and missed pills recorded. Results of check not reported.
(Continued)
articles, studies in which riboflavin was not administered, or intervention studies in which riboflavin was administered only in combination with other nutrients. Thirty-six articles appeared to be potentially relevant and were collected as full-text articles to be assessed for inclusion. Eighteen articles were subsequently excluded for the reasons listed in Figure 1 , which left 18 supplementation studies (reported in 18 publications) that fulfilled the inclusion criteria. In total, 14 biomarkers of riboflavin status were identified, but, for the majority of these, data were available only from one or 2 studies (Figure 1) so it was not possible to determine the effectiveness of the particular biomarker as an indicator of a change in intake. The main focus of this systematic review, therefore, was on the assessment of the responses of EGRac, on basal (unstimulated) EGR activity, and on plasma total homocysteine as potential biomarkers of riboflavin status because more than one study was found to have reported on each of these outcomes.
EGRac
Fifteen supplementation studies assessed EGRac, but one was not included in the meta-analysis because the required data were not available (23) . The remaining 14 studies included 640 participants in studies ranging from 7 (22) to 48 participants per arm (33) . Seven studies were conducted with children and adolescents (22, 23, 29, 32, 33, 38 ; the last of these involved males only), 4 were conducted with pregnant and lactating women (11, 21, 36) , 2 were conducted with adults (25, 30 ; the latter study involved males only), and 2 were conducted with elderly populations (15, 27) . The majority of studies (10 of 14) were in populations from developing countries, mainly from Gambia (11, 21, 23, 29, 30, 32, 33, 36) , and the remainder in populations from developed countries (15, 22, 25, 27, 38) . Three of the latter studies selected participants on the basis of having high riboflavin status at baseline as determined by EGRac (ie, . 1.2; 15, 25, 27) . Study duration ranged from 2-3 wk (22) to 52 wk (33) . Nine studies administered the supplements daily, which ranged from physiologic doses of 1 mg (29) to pharmacologic doses of 60 mg (22) . Five studies administered riboflavin on a nondaily basis with doses ranging from 2 to 15 mg administered either once every 2 wk or 6 times/wk. One study involved a preload with 5 mg riboflavin for 1 mo before supplementation with doses ranging from 0.5 to 2.0 mg/d (29) . EGRac was measured in all studies by an enzyme assay. For further details (ie, the characteristics of the included studies), see Table 1 .
Fourteen studies were randomized (15, 21-23, 25, 27, 30-34, 36, 37) with most providing some details on the method of randomization. Reasons for dropouts and exclusions were given in 11 studies, and there were no dropouts in another 3 studies. Compliance was monitored in 14 studies by observing the taking of the supplements (9 studies) or by pill counts (5 studies). Only 2 studies reported the results of the pill counts, and the dose delivered was not checked in any of the studies. For further details (ie, the quality of the included studies), see Table 2 . (22) RCT. Divided into 2 groups on the basis of sex and swimming performance level.
Not reported so assumed there were none.
None mentioned.
1 RCT, randomized controlled trial; PCV, packed cell volume.
The forest plot of the EGRac response to riboflavin supplementation is shown in Figure 2 . EGRac was significantly lowered by intervention with riboflavin in both the RCTs (10 studies) and the nonrandomized controlled trials (CCTs; 4 studies); for EGRac, a negative value indicates an improvement in status. The overall effect was stronger in the RCTs [weighted mean difference (WMD): 20.41; 95% CI: 20.56, 20.26; n ¼ 407; P , 0.00001] than in the nonrandomized controlled trials (WMD: 20.66; 95% CI: 21.16, 20.16; n ¼ 233; P ¼ 0.01), although heterogeneity was significant for both (I 2 .97.5%), which indicates that EGRac might be a useful marker in some circumstances but not in others. Subgroup analysis was carried out to attempt to explain the heterogeneity, and the results are shown in Table 3 . For the majority of secondary analyses, insufficient data were available to answer the questions posed. Children and adolescents and pregnant and lactating women were the only age groups in which sufficient data were available to claim that EGRac accurately reflects a change in riboflavin intake. EGRac response was dependent on baseline status because a greater decrease in EGRac values occurred in populations from developing countries with low riboflavin status at baseline (P , 0.00001) than in populations from developed countries with moderate-to-high baseline status (P , 0.01; Figure 3 ). In addition, the dose appeared to be important. Riboflavin doses consistent with recommended dietary concentrations ('1.6 mg) over study durations of 4-12 wk caused a small but significant decrease in EGRac (P ¼ 0.004), but when the dose was increased to moderate concentrations (ie, 2-5 mg), the overall effect was stronger (P , 0.00001). The test for heterogeneity remained significant for all of the subgroup analysis (I 2 .82.2%), which indicates that population subgrouping did not appear to explain the heterogeneity seen. To explore whether duration of supplementation had an effect on response, studies that measured EGRac at more than one time point postsupplementation were selected. Figure 4 shows that EGRac decreased in response to supplementation by the first time point (at 2 or 3 wk) with no further change observed at subsequent time points in populations from developing countries. The exception was the study by Bates et al (36) in which high-dose riboflavin was administered at 2-wk intervals (15 mg; equivalent to '2 mg/d), and little or no response was observed after 4 wk.
Basal EGR activity
Although generally considered to be a less useful marker than EGRac, some studies (n ¼ 5) reported basal EGR activity in FIGURE 2. The effect of supplementation with riboflavin on erythrocyte glutathione reductase activation coefficient (EGRac). A higher EGRac ratio indicates a lower riboflavin status. Values are mean (6SD) change from baseline (25, 32) or absolute values postintervention (11, 15, 21, 22, 27, 29, 30, 33, 36, 38) . RCT, randomized controlled trials; CCT, nonrandomized controlled trials; WMD, weighted mean difference. addition to EGRac (21, 29, 33) . These studies included 251 lactating women and children from developing populations in studies ranging from 13 (21) to 48 participants per arm (33) . For further details of study characteristics and study quality, see Tables 1 and 2 .
The forest plot of basal EGR activity response to riboflavin supplementation is shown in Figure 5 . Basal activity of the enzyme increased significantly in response to intervention with riboflavin in both the RCTs (3 studies; WMD: 129 lmol/g hemoglobin/h; 95% CI: 97, 162; n ¼ 151; P , 0.00001) and the nonrandomized controlled trials (2 studies; WMD: 161 lmol/g hemoglobin/h; 95% CI: 119, 203; n ¼ 100; P , 0.00001), although heterogeneity was significant in the RCTs (I 2 : 72%). Insufficient data were available to carry out detailed subgroup analysis to attempt to explain the heterogeneity other than to compare the response in children and adolescents to that in lactating women. Basal EGR activity was found to reflect a change in riboflavin intake in both population groups (in children and adolescents-3 studies; WMD: 135 lmol/g hemoglobin/h; 95% CI: 89, 182; n ¼ 196; P , 0.00001; I 2 : 68.9%; in lactating females-2 studies; WMD: 148 lmol/g hemoglobin/ h; 95% CI: 89, 206; n ¼ 55; P , 0.00001; I 2 : 82%).
Plasma total homocysteine
Three RCTs assessed plasma total homocysteine concentrations (24, 27, 37) , and these studies included 106 participants in studies ranging from 7 to 23 participants per arm. Two studies measured plasma total homocysteine concentrations by immunoassay (25, 27) , and one used HPLC (37) . For further details of study characteristics and study quality, see Tables 1 and 2 .
The forest plot of plasma total homocysteine response to riboflavin supplementation (not shown) showed that homocysteine concentrations did not respond to supplementation with riboflavin (3 studies; WMD: 0.1 lmol/L; 95% CI: 20.3, 0.5 lmol/L; n ¼ 106; P ¼ 0.56). One study (25) assessed response in plasma total homocysteine according to the MTHFR 677C/T genotype, with 89 participants randomized by genotype group (CC, CT, or TT) to riboflavin or placebo. Plasma total homocysteine concentrations decreased significantly in those with the TT genotype (WMD: 25.9 lmol/L; 95% CI: 210. 5, 21.3 lmol/L; n ¼ 27; P ¼ 0.01), but this effect was not observed in those with either the wild-type (CC; P ¼ 0.26) or heterozygous (CT; P ¼ 0.44) genotypes for MTHFR 677C/T.
Other biomarkers
The effectiveness of riboflavin concentrations in plasma, erythrocytes, urine, and breast milk and the activity of the FMNdependent enzyme, PPO, as biomarkers of riboflavin status could not be evaluated because each of these were measured by only one study. The outcome as reported in the original publication is shown in Table 4 . Plasma and erythrocyte concentrations of FAD and FMN (except plasma FAD) and plasma concentrations of riboflavin (24) , breast-milk riboflavin concentrations (21) , urinary excretion of riboflavin (31) , and activity of the functional biomarker PPO (11) might have potential as biomarkers of riboflavin status in that each showed a significant response to riboflavin intervention in the original publication.
DISCUSSION
In the 36 articles initially identified as potentially relevant (Figure 1 ), our systematic review identified 18 studies that Unclear but likely to be useful measured the response of 14 different biomarkers to supplementation with riboflavin. Sufficient data were available to suggest that the functional biomarker, EGRac, and the basal activity of GR respond to intervention with riboflavin in populations from developing countries. EGRac is also a useful marker in populations with marginal-to-normal baseline riboflavin status. Substantial heterogeneity among studies that measured EGRac, which could not be explained by subgrouping in the secondary analysis, was observed. Plasma total homocysteine was found to be an ineffective biomarker of riboflavin status, except perhaps in those with the MTHFR 677 TT genotype. The evidence was insufficient to establish whether riboflavin concentrations in biological samples such as blood, urine, and breast milk or PPO activity, an alternative functional biomarker to EGRac, have potential as markers of riboflavin status. The variability in EGRac response among studies was to be expected because the studies differed in many aspects, most notably in the population investigated. Two-thirds of the included studies were carried out in populations from developing countries, so limited data were available for healthy populations. Furthermore, the dose and frequency of administering the supplements varied among studies with many providing the supplements on a nondaily basis. Other weaknesses of the included studies were that most studies were of a small sample size and those from developing countries focused mainly on children and adolescents and on pregnant and lactating women living in Gambia, whereas half of the studies from developed countries were carried out in the same country and involved adults or elderly people. In addition, one-third of the included studies did not measure the response of specific biomarkers of riboflavin status to supplementation as a primary outcome. The above limitations prevented a separate meta-analysis from being carried out for developed and developing countries. Furthermore, because limited data were available for the secondary analysis to explore the factors that might contribute to the variability in EGRac response among studies, our overall conclusions with respect to (25, 32) or absolute values postintervention (11, 15, 21, 22, 27, 29, 30, 33, 36, 38) . WMD, weighted mean difference.
this biomarker were weakened and should be interpreted with caution.
EGRac was found to be a sensitive and specific biomarker of a change in riboflavin intake over supplementation periods of at least 4 wk with doses ranging from 1.0 to 5.0 mg except for 2 studies where pharmacologic doses of 25 mg (15) and 60 mg (22) were used. The latter study, however, was the only study to show no effect of supplementation, and this was likely owing to the subjects having optimum status at baseline: EGRac values were close to 1.0, which suggests that the enzyme GR was saturated with its cofactor FAD (22) . In studies from developing countries that measured EGRac response at more than one time point after supplementation, with doses of riboflavin ranging from 2 to 15 mg, a general pattern was observed. After an initial rapid decline in EGRac, values reached a plateau by 2-3 wk of supplementation, although mean EGRac values generally remained above the cutoff typically used to define deficiency (ie, EGRac 1.3). Even in healthy populations with normal baseline values (EGRac ranging from 1.1 to 1.2), EGRac showed a small but significant response to intervention with doses equivalent to current dietary recommendations, which offers some support for recent concerns that suboptimal riboflavin status might be a considerable problem across all population age groups. National surveys from the United Kingdom show that the prevalence of EGRac 1.3 was 75% and 87% among boys and girls aged 4-18 y, respectively, (39) , and although prevalence decreased with increasing age, 41% of adults aged .65 y had suboptimal status (14) . The high prevalence of suboptimal status among young people, especially adolescent girls, appeared to be because of an age-related decline in milk consumption. Over 20% of girls aged 11-18 y had intakes below the lower reference nutrient intake. This did not appear to be the case for the high prevalence of EGRac 1.3 among older people because only 5% of men and 9% of women had intakes below the lower reference nutrient intake (14) . However, there is uncertainty about the cutoff that should be used to define riboflavin deficiency. An early study that described the EGRac test as a useful measure of riboflavin status proposed a value of 1.2 to indicate low or deficient status (40) , but changes to the assay methodology have led to the acceptance of a cutoff 1.3, and although there is no consensus between laboratories regarding quality controls, as for other micronutrients, some investigators have proposed that this cutoff value should be further increased (29, 36) . Additional studies are clearly required to reevaluate the cutoff for EGRac to determine whether suboptimal status is a real problem among different age and sex groups or, as argued by 12 (41) . Insufficient data were available to draw conclusions about the efficacy of riboflavin concentrations in biological samples such as blood, urine, and breast milk or the activity of the enzyme PPO as biomarkers of riboflavin status. A number of studies have measured riboflavin vitamers in biological samples, in particular plasma and erythrocytes, but the results are inconsistent. Generally, FMN is considered a more useful marker than FAD, and riboflavin as FAD appears to be relatively stable to a change in intake (24, 42) . Furthermore, erythrocytes are considered to be a more useful sample than plasma or serum because riboflavin cofactors are concentrated in erythrocytes (43) . PPO has been proposed as an alternative functional biomarker to EGRac (11) because it has been shown that cells have a tendency to spare FAD at the expense of FMN and riboflavin; therefore, under the condition of riboflavin deficiency, the activity of PPO (which is FMN dependent) would be expected to decrease before any detectable activity changes in GR. Further studies that investigate the potential of blood vitamers and PPO activity as markers of riboflavin status are warranted.
The current review shows that plasma total homocysteine is not an effective biomarker of riboflavin status in the general population. FAD is required as a cofactor for the folate-metabolizing enzyme MTHFR, which in turn is involved in homocysteine metabolism. Observational studies in European populations have shown that riboflavin status is an important determinant of plasma total homocysteine concentrations in people homozygous (TT genotype) for the common 677C/T polymorphism in MTHFR (44, 45) . Only one study (included in this review), however, has specifically looked at the effect of riboflavin supplementation on plasma total homocysteine concentrations in individuals with and without this polymorphism (25) . That study showed that homocysteine concentrations were lowered by low-dose riboflavin supplementation but only in healthy adults homozygous with the mutant TT genotype, which suggests an important gene-nutrient interaction. The frequency of this polymorphism ranges from 4% to 26% in Europe and is higher in southern than in northern countries (26) . Further studies are required to confirm this genenutrient interaction so that riboflavin requirements of people with this common genetic predisposition to elevated homocysteine are considered in emerging dietary recommendations. This might have public health relevance given that the MTHFR 677 TT genotype is associated with a higher risk of diseases such as cardiovascular disease and osteoporosis (46) .
The process of study selection highlighted that the quality of published data are often poor. Common data-related problems in publication that were identified were the following: the omission of any measure of variance in the presentation of data; the lack of clarity regarding the number of subjects who started the intervention, completed the intervention, and were included in the statistical analysis; the omission of data for the control group; and limited details in reporting the assay methodology. Authors should consider these issues when publishing future studies.
This review highlights a number of gaps in the field of riboflavin research. Studies of healthy populations from developed countries are required to establish whether or not suboptimal riboflavin status is a real problem among different age and sex groups. Research is also necessary to establish riboflavin requirements of individuals with different MTHFR genotypes. The evidence will be useful for generating dietary recommendations for riboflavin that not only are specific to different age and sex groups but also meet the requirements of those with commonly occurring genetic variants. (Other articles in this supplement to the Journal include references 16 and 47-53.) We thank the authors of the main methodology article (16) for running the electronic searches and for their assistance and guidance with all aspects of data collection and analysis. We also thank the authors of the original articles, in particular those who were approached for additional information.
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